Skip to content

Effect of Probiotic Supplementation on Endothelial Function

Effect of Probiotic Supplementation on Endothelial Function in Men With Coronary Artery Disease

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01952834
Enrollment
21
Registered
2013-09-30
Start date
2013-06-30
Completion date
2015-03-31
Last updated
2016-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

coronary artery disease, probiotic, endothelial function, brachial artery, ntric oxide

Brief summary

The study is being performed to determine whether probiotics (GoodBelly) improves blood vessel function.Probiotics similar to yogurt are living micro-organisms (beneficial to its host) the lives in the intestine. Patients who have coronary artery disease will be enrolled in this study. The research results will be used to determine if the type of bacteria present in the intestines play a role in the pathogenesis of cardiovascular disease. Patients with coronary artery disease will be enrolled for up to 12 weeks. Patients will take the probiotic for 6 weeks. Following the 6 week period there is a washout period of 4 weeks, and an optional antibiotic study called vancomycin. Patients will take the vancomycin for 10 days. Blood vessel function will be measured by ultrasound before and after the probiotic supplement and vancomycin antibiotic. Blood will also be taken before and after to evaluate for markers of inflammation.

Detailed description

We plan to recruit 20 patients, men with coronary artery disease, for this single center, interventional trial with the Probiotic-GoodBelly followed by Vancomycin. The study includes 6 total visits. Subjects who pass a phone screen will be invited to a screening visit for study eligibility (Visit 1) Informed consent will be reviewed; a unique study number will be assigned once written informed consent is obtained (no subject will be assigned more than 1 allocation number); relevant participant medical history will be recorded including currently prescribed medications; anthropometric measurements will be taken (height, weight, and waist circumference in metric units) and blood pressure will be recorded (measured in triplicate and averaged). Subjects will be allowed to take their blood pressure medication on the morning of their screening visit, but not the mornings of any of the other study visits to limit the acute influence of these medications on endothelial function. If the potential participant qualifies for the study, he will return 1 week after the screen for a study visit(Visit 2) where he will turn in his stool sample, undergo initial tests of endothelial function and receive 3 week supply of GoodBelly Probiotic. After 3 weeks he will have to return (Visit 3) for another 3 week supply of his probiotic. After a total of 6 weeks of taking the probiotic he will have to return (Visit 4) with his stool sample. He will be asked to fast for 6-8 hours prior to the visit to limit the acute dietary influences on vascular endothelial function. During Visit 4, endothelial function will determined by brachial artery reactivity testing His stool samples will be collected and blood samples will also be taken at this visit for systemic measurements inflammatory markers. If he agrees to the optional Vancomycin study. He will return after 4 weeks for (Visit 5). He will be asked to fast for 6-8 hours prior to the visit to limit the acute dietary influences on vascular endothelial function. At Visit 5, endothelial function will determined by brachial artery reactivity testing His stool samples will be collected and blood samples will also be taken at this visit for systemic measurements inflammatory markers. He will then be given a 10 day supply of vancomycin. After 10 days he will return (Visit 6) with his stool sample. At Visit 6, endothelial function will determined by brachial artery reactivity testing . His stool samples will be collected and blood samples will also be taken at this visit for systemic measurements inflammatory markers.

Interventions

DIETARY_SUPPLEMENTGoodBelly Probiotic

GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days

DRUGVancomycin

GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days

Sponsors

Medical College of Wisconsin
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Age between 40-75 years old 2. Male sex 3. History of known coronary artery disease (by either history of myocardial infarction, angiogram demonstrative \>=50% stenosis in at least 1 major epicardial coronary artery, or a previous stress test that showed evidence of ischemia that has not been revealed to be a false positive test by angiography)

Exclusion criteria

1. Unstable angina or myocardial infarction by history, ECG, and/or enzymatic criteria within 1 month of enrollment. 2. Left ventricular dysfunction as defined by an left ventricular ejection fraction documented as \< 45% within 1 year of enrollment by an echocardiogram, MRI, or nuclear imaging. 3. Uncontrolled hypertension with a blood pressure greater than 170/100 mmHg at the screening visit. 4. Known history of chronic renal insufficiency, liver dysfunction, or cancer besides non-melanoma skin carcinomas or localized prostate cancer requiring systemic treatment within five years of enrollment. 5. Known history of cognitive impairment or inability to follow study procedures 6. Patient with an implanted defibrillator or permanent pacemaker on with the potential participant is known to rely upon for greater than 50% of ventricular depolarizations. 7. Patients who received probiotics, prebiotics, and antibiotics in the last 12 weeks. 8. Patients with dosing changes of vasoactive medications and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the 6 weeks prior to enrollment.

Design outcomes

Primary

MeasureTime frameDescription
Brachial Artery Flow Mediated Dilation% Change before and after 6 weeks of daily ProbioticA measurement of endothelial function in humans that reports the percent change in brachial artery diameter to a flow stimulus in the arm induced by 5 minutes of occlusion of flow to the arm. It is measured as the percent change from baseline diameter.

Secondary

MeasureTime frameDescription
Interleukin 8Change before and after 6 weeks of daily ProbioticCirculating cytokine measured in the plasma
Interleukin-12Change before and after 6 weeks of probioticThis is a circulating plasma cytokine

Countries

United States

Participant flow

Participants by arm

ArmCount
GoodBelly Probiotic and Vancomycin
Good Belly Probiotic 2.7 oz Daily x 6 weeks Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days GoodBelly Probiotic: GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days Vancomycin: GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
21
Total21

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyAdverse Event1

Baseline characteristics

CharacteristicGoodBelly Probiotic and Vancomycin
Age, Continuous64 years
STANDARD_DEVIATION 7
History of Hypertension
Hypertensive
11 participants
History of Hypertension
Non-Hypertensive
10 participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
21 Participants
Region of Enrollment
United States
21 participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
21 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 21
serious
Total, serious adverse events
1 / 21

Outcome results

Primary

Brachial Artery Flow Mediated Dilation

A measurement of endothelial function in humans that reports the percent change in brachial artery diameter to a flow stimulus in the arm induced by 5 minutes of occlusion of flow to the arm. It is measured as the percent change from baseline diameter.

Time frame: % Change before and after 6 weeks of daily Probiotic

ArmMeasureValue (MEAN)Dispersion
GoodBelly Probiotic and VancomycinBrachial Artery Flow Mediated Dilation1.2 percent changeStandard Deviation 1.6
Primary

Brachial Artery Flow Mediated Dilation

Flow Mediated Dilation is measured as the percent change in brachial artery diameter as measured by high resolution ultrasound based on arterial diameter prior to and following 5 minute flow occlusion to the forearm . We measured the percent change in brachial diameter before vancomycin was started and again 10 days after vancomycin

Time frame: Change before and after 10 days of Vancomycin, approximately 12 weeks from baseline

Population: Subgroup analyzed who volunteered to have vancomycin

ArmMeasureValue (MEAN)Dispersion
GoodBelly Probiotic and VancomycinBrachial Artery Flow Mediated Dilation-0.2 percent changeStandard Deviation 2
Secondary

Interleukin-12

This is a circulating plasma cytokine

Time frame: Change before and after 6 weeks of probiotic

Population: Subjects with plasma samples available pre and post probiotic supplementation

ArmMeasureValue (MEAN)Dispersion
GoodBelly Probiotic and VancomycinInterleukin-12-10.4 pg/mLStandard Error 3.9
Secondary

Interleukin 8

Circulating cytokine measured in the plasma

Time frame: Change before and after 6 weeks of daily Probiotic

ArmMeasureValue (MEAN)Dispersion
GoodBelly Probiotic and VancomycinInterleukin 8-3.5 pg/mLStandard Error 1.3

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026